Carl Gordon Biography and Net Worth

Director of Compass Therapeutics

Founding Member, Managing Partner, and Co-Head of Global Private Equity, OrbiMed Advisors LLC

Carl L. Gordon, PhD, CFA, is a Founding Member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of several public and private companies. He received a B.A. in Chemistry from Harvard College, a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.

What is Carl L. Gordon's net worth?: The estimated net worth of Carl L. Gordon is at least $17.76 million as of February 14th, 2025. Gordon owns 3,205,930 shares of Compass Therapeutics stock worth more than $17,760,852 as of December 5th. This net worth approximation does not reflect any other assets that Gordon may own. Learn More about Carl L. Gordon's net worth.
How do I contact Carl L. Gordon?: The corporate mailing address for Gordon and other Compass Therapeutics executives is , , . Compass Therapeutics can also be reached via phone at 617-500-8099 and via email at [email protected]. Learn More on Carl L. Gordon's contact information.
Has Carl L. Gordon been buying or selling shares of Compass Therapeutics?: Carl L. Gordon has not been actively trading shares of Compass Therapeutics in the last ninety days. Most recently, Carl L. Gordon sold 3,571,428 shares of the business's stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.59, for a transaction totalling $5,678,570.52. Learn More on Carl L. Gordon's trading history.
Who are Compass Therapeutics' active insiders?: Compass Therapeutics' insider roster includes Jonathan Anderman (Insider), Carl Gordon (Director), and Thomas Schuetz (CEO). Learn More on Compass Therapeutics' active insiders.
Are insiders buying or selling shares of Compass Therapeutics?: During the last twelve months, Compass Therapeutics insiders bought shares 2 times. They purchased a total of 30,000 shares worth more than $51,900.00. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 3,571,428 shares worth more than $5,678,570.52. The most recent insider tranaction occured on May, 27th when CEO Thomas J Schuetz bought 10,000 shares worth more than $21,100.00. Insiders at Compass Therapeutics own 29.8% of the company. Learn More about insider trades at Compass Therapeutics.
Information on this page was last updated on 5/27/2025.

Carl L. Gordon Insider Trading History at Compass Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/9/2025	Sell	3,571,428	$1.59	$5,678,570.52
5/13/2022	Buy	30,722	$2.49	$76,497.78	14,817,994
5/11/2022	Buy	64,700	$1.79	$115,813.00	14,690,178
11/4/2021	Buy	5,357,143	$3.50	$18,750,000.50

Carl L. Gordon Buying and Selling Activity at Compass Therapeutics

Compass Therapeutics Company Overview

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $5.54

$5.25

$5.61

50 Day Range

MA: $4.37

$3.36

$5.90

2 Week Range

Now: $5.54

$1.33

$5.86

Volume

1,473,044 shs

Average Volume

2,123,114 shs

Market Capitalization

$985.34 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.44